ArticlePloS one2017
Aging and death-associated changes in serum albumin variability over the course of chronic hemodialysis treatment.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Pre-Frailty and Frailty in Dialysis and Pre-Dialysis Patients: A Systematic Review of Clinical and Biochemical Markers.International journal of environmental research and public health · 2021Pooled it
- Frequency of Routine Bloodwork Among Patients With Chronic Kidney Disease: A Narrative Review to Inform Appropriateness of Care.Canadian journal of kidney health and disease · 2026Review
- Construction and validation of a cross-sectional risk classification model for hypoproteinemia in single-center maintenance hemodialysis patient.Scientific reports · 2025Article
- Differences in association between hypoalbuminaemia and mortality among younger versus older patients on haemodialysis.Clinical kidney journal · 2025Article
- Article
- Organophosphorus Poisoning: Acute Respiratory Distress Syndrome (ARDS) and Cardiac Failure as Cause of Death in Hospitalized Patients.International journal of molecular sciences · 2023Review
- Intercorrelated variability in blood and hemodynamic biomarkers reveals physiological network in hemodialysis patients.Scientific reports · 2023Article
- Synchrony of biomarker variability indicates a critical transition: Application to mortality prediction in hemodialysis.iScience · 2022Article
- An objective metric of individual health and aging for population surveys.Population health metrics · 2022Article
- Prediction of Mortality in Hemodialysis Patients Using Moving Multivariate Distance.Frontiers in physiology · 2021Article
- Estimation of homeostatic dysregulation and frailty using biomarker variability: a principal component analysis of hemodialysis patients.Scientific reports · 2020Article
- Rejuvenation of three germ layers tissues by exchanging old blood plasma with saline-albumin.Aging · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSeveral epidemiological studies have demonstrated associations between variability in a number of biological parameters and adverse outcomes. As the variability may reflect impaired homeostatic regulation, we assessed albumin variability over time in chronic hemodialysis (HD) patients.
methodsData from 1346 subjects who received chronic HD treatment from May 2001 to February 2015 were analyzed according to three phases of HD treatment: post-HD initiation, during maintenance HD treatment, and before death. The serum albumin values were grouped according to the time interval from HD initiation or death, and the yearly trends for both the albumin levels and the intra-individual albumin variability (quantified by the residual coefficient of variation: Alb-rCV) were examined. The HD initiation and death-associated changes were also analyzed using generalized additive mixed models. Furthermore, the long-term trend throughout the maintenance treatment period was evaluated separately using linear regression models.
resultsAlbumin levels and variability showed distinctive changes during each of the 3 periods. After HD initiation, albumin variability decreased and reached a nadir within a year. During the subsequent maintenance treatment period (interquartile range = 5.2-11.0 years), the log Alb-rCV showed a significant upward trend (mean slope: 0.011 ± 0.035 /year), and its overall mean was -1.49 ± 0.08 (equivalent to an Alb-rCV of 3.22%). During the 1-2 years before death, this upward trend clearly accelerated, and the mean log Alb-rCV in the last year of life was -1.36 ± 0.17. The albumin levels and variability were negatively correlated with each other and exhibited exactly opposite movements throughout the course of chronic HD treatment. Different from the albumin levels, albumin variability was not dependent on chronological age but was independently associated with an individual's aging and death process.
conclusionThe observed upward trend in albumin variability seems to be consistent with a presumed aging-related decline in homeostatic capacity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.